Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
PTLA is in the long-term down -65% below S&P in 3 years.
Description: Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company?s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen t
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-2.28%||Sales Growth - Q/Q||-2.2%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-31.53%||ROE||-36.59%||ROI|
|Current Ratio||9.89||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.1|
|Gross Margin||Operating Margin||-1592.24%||Net Profit Margin||-1595.01%||Dividend Payout Ratio|
|Cash From Financing Activities||113.04 M||Cash From Investing Activities||9.44 M||Cash From Operating Activities||-47.15 M||Gross Profit|
|Net Profit||-46.91 M||Operating Profit||-46.5 M||Total Assets||486.3 M||Total Current Assets||403.45 M|
|Total Current Liabilities||40.79 M||Total Debt||Total Liabilities||67.32 M||Total Revenue||2.36 M|
|High 52 week||37.76||Low 52 week||15.46||Last close||30.94||Last change||1.91%|
|RSI||68.73||Average true range||1.39||Beta||1.71||Volume||8.33 M|
|Simple moving average 20 days||15.82%||Simple moving average 50 days||15.78%||Simple moving average 200 days||14.08%|
|Performance Week||24.76%||Performance Month||18.27%||Performance Quart||-2.7%||Performance Half||8.41%|
|Performance Year||-17.97%||Performance Year-to-date||58.5%||Volatility daily||3.23%||Volatility weekly||7.23%|
|Volatility monthly||14.81%||Volatility yearly||51.32%||Relative Volume||1513.75%||Average Volume||1.04 M|
|New High||New Low|
2020-01-17 12:04:00 | PORTOLA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Portola Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
2020-01-17 10:22:13 | Portola Pharmaceuticals Shareholder Alert - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Investors of Portola Pharmaceuticals – Class Action Filed Against PTLA
2020-01-10 17:24:00 | Lost Money in Portola Pharmaceuticals, Inc.?
2020-01-10 15:19:58 | Portola Pharmaceuticals Slump Ignites Heavy Call Trading
2020-01-10 10:01:00 | Portola's stock falls on weak Andexxa sales
2020-01-10 07:13:12 | The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
2019-12-23 08:30:00 | Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020
2019-12-10 12:06:10 | Why health care innovation is where investors should look
2019-12-09 15:21:00 | Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
2019-12-09 09:52:46 | Should You Buy Portola Pharmaceuticals Inc PTLA?
2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
2019-11-08 11:31:04 | Pacira's PCRX Q3 Earnings Top Estimates, Revenues Rise Y/Y
2019-11-07 09:22:11 | Portola Pharmaceuticals, Inc. NASDAQ:PTLA: Is Breakeven Near?
2019-11-06 11:35:26 | Edited Transcript of PTLA earnings conference call or presentation 5-Nov-19 9:30pm GMT
2019-11-06 10:41:03 | Mallinckrodt MNK Q3 Earnings Beat, Stock Down on Sales Miss
2019-11-05 18:05:11 | Portola Pharmaceuticals PTLA Reports Q3 Loss, Tops Revenue Estimates
2019-11-05 11:17:04 | Bausch BHC Beats on Q3 Earnings & Sales, Raises Guidance
2019-11-05 10:42:03 | Endo ENDP Q3 Earnings & Revenues Beat Estimates, Down Y/Y
2019-11-01 16:30:00 | Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635c4
2019-11-01 11:07:03 | WIll Allergan AGN Beat Estimates This Earnings Season?
2019-10-30 12:01:04 | Guardant Health GH to Report Q3 Earnings: What's in Store?
2019-10-29 09:46:01 | Catalyst Pharma CPRX to Post Q3 Earnings: What's in Store?
2019-10-28 09:59:23 | Portola Pharmaceuticals Inc PTLA: Are Hedge Funds Right About This Stock?
2019-10-28 09:38:01 | Sony SNE to Report Q2 Earnings: What's in the Offing?
2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
2019-09-19 08:20:00 | Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
2019-08-22 08:30:00 | Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2019-08-16 11:08:39 | Here's Why Portola Pharmaceuticals NASDAQ:PTLA Can Afford Some Debt
2019-08-13 19:32:00 | Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2019-08-12 16:43:00 | Portola Pharmaceuticals Announces Proposed Offering of Common Stock